Navitoclax dihydrochloride

Synonyms: ABT-263 dihydrochloride
Navitoclax dihydrochloride (ABT-263 dihydrochloride) 是一种具有口服活性的 BH3 模拟剂,也是 Bcl-2、Bcl-xL 和 Bcl-w 的抑制剂,对每个靶点的 Ki 值均 <1 nM,可通过触发内源性凋亡 (Apoptosis) 并下调 Survivin 和 TGFβ2 的表达来减轻纤维化、引发血小板减少症,对多种肿瘤具有抗癌活性,还可增强化疗和放疗的效果,可用于急性淋巴细胞白血病、卵巢癌以及纤维化疾病的研究。
产品编号: MS-D14119 CAS No.: 1093851-28-5 分子式: C47H57Cl3F3N5O6S3 分子量: 1047.53
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

Navitoclax dihydrochloride (ABT-263 dihydrochloride) 是一种具有口服活性的 BH3 模拟剂,也是 Bcl-2、Bcl-xL 和 Bcl-w 的抑制剂,对每个靶点的 Ki 值均 <1 nM,可通过触发内源性凋亡 (Apoptosis) 并下调 Survivin 和 TGFβ2 的表达来减轻纤维化、引发血小板减少症,对多种肿瘤具有抗癌活性,还可增强化疗和放疗的效果,可用于急性淋巴细胞白血病、卵巢癌以及纤维化疾病的研究。

生物实验数据

生物活性 Navitoclax dihydrochloride (ABT-263 dihydrochloride) is an orally active BH3 mimetic and an inhibitor of Bcl-2, Bcl-xL, and Bcl-w with Ki values of <1 nM for each target, which triggers intrinsic apoptosis and downregulates Survivin and TGFβ2 expression, alleviates fibrosis, induces thrombocytopenia, exhibits anticancer activity against multiple tumors, enhances the effects of chemotherapy and radiotherapy, and can be used for research on acute lymphoblastic leukemia, ovarian cancer, and fibrotic diseases.
IC50 & Target

Bcl-2

<1 nM (Ki)

Bcl-xL

<1 nM (Ki)

Bcl-W

<1 nM (Ki)

体外研究
(In Vitro)

Navitoclax (1 nM-10 μM; 96 h) dihydrochloride 在体外对多种癌细胞系表现出细胞毒活性,其中急性淋巴细胞白血病 (ALL) 和 Kasumi-1 急性髓系白血病 (AML) 细胞系的敏感性最高 (ALL 中位 IC50 = 0.45 μM,RS4;11 细胞系 IC50 = 0.05 μM,Kasumi-1 细胞系 IC50 = 0.09 μM),所有受试细胞系的中位 IC50 为 1.91 μM。
Navitoclax dihydrochloride 可强效结合抗凋亡 Bcl-2、Bcl-xL 和 Bcl-w 蛋白,每种蛋白对应的 Ki 均 <1 nM。
Navitoclax (72 h) dihydrochloride 可在 46 种实体肿瘤细胞系中与多种化疗试剂产生协同作用,其平均联合指数值范围为 0.05 至 0.75。
Navitoclax (0.1-25.0 μM; 2 h) dihydrochloride 在 Docetaxel (MS-X28387) 预处理的卵巢癌细胞 SKOV3 中诱导浓度依赖性的 Caspase-3 活化。
Navitoclax dihydrochloride 可高亲和力结合纯化的 BCL-2 和 BCL-XL 抗凋亡蛋白,但不结合 MCL-1 蛋白。
Navitoclax dihydrochloride 可在 BCL-2 缺陷细胞中微弱诱导细胞凋亡,表明其具有 BCL-2 依赖性凋亡活性。
Navitoclax (1.0 nM-10.0 μM) dihydrochloride 在受试癌细胞系中,对急性淋巴细胞白血病 (ALL) 细胞系表现出最高敏感性,其敏感性与 BCL-2、BCL-W、BCL-XL 和 BIM 的高表达以及 MCL-1 的低表达相关。
Navitoclax (14 nM-3 μM; 72 h) dihydrochloride 在与 Paclitaxel (HY-B0015) 联合作用时,对 27 株卵巢癌细胞系中的 26 株表现出超叠加性生长抑制作用,其中 14 株细胞系存在强协同效应 (Bliss sum >250);其单试剂 IC50 值范围为:OAW28 细胞中 0.04 μM 至 TOV112D 细胞中 1.3 μM。

Cell Cytotoxicity Assay

Cell Line: 23 pediatric cancer cell lines from the Pediatric Preclinical Testing Program (PPTP) in vitro panel, including rhabdomyosarcoma, rhabdoid, Ewing sarcoma, glioblastoma, neuroblastoma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), anaplastic large cell lymphoma (ALCL), and non-Hodgkin lymphoma (NHL) lines
Concentration: 1 nM, 10 μM
Incubation Time: 96 h
Result: Induced cytotoxicity against approximately half of the tested cell lines.
Exhibited a median IC50 of 1.91 μM across all 23 cell lines, with IC50 values ranging from 0.05 μM to >10 μM.
Showed the greatest sensitivity in ALL cell lines, with a median IC50 of 0.45 μM, significantly lower than the median IC50 of >10 μM for non-ALL lines (P=0.02).
Demonstrated high sensitivity in the AML line Kasumi-1, with an IC50 of 0.09 μM.
Had a higher median IC50 of >10 μM in Ewing sarcoma lines compared to non-Ewing lines (median IC50 1.14 μM, P=0.19).
Achieved IC50 values <1 μM for 9 of the 23 cell lines, a concentration defined as indicative of sensitivity.

Immunofluorescence

Cell Line: SKOV3 human ovarian cancer cells
Concentration: 0.1-25.0 μM
Incubation Time: 2 h (following 48 h docetaxel pretreatment)
Result: Did not increase activated caspase-3 levels alone.
Induced a concentration-dependent increase in the percentage of cells with activated caspase-3 when preceded by docetaxel pretreatment, reaching up to ≈25% at 25.0 μM.
体内研究
(In Vivo)

Navitoclax (100 mg/kg;口服;每日 1 次;第 2-21 天、第 2-3 天、第 2-15 天) dihydrochloride 在 SKOV3 卵巢癌异种移植模型中无效,但可显著增强 Docetaxel 在多种联合及序贯处理方案下的抗肿瘤活性,并提升 ORR、TGI 和 TGD。
Navitoclax (100 mg/kg;口服;每日 1 次;连续 21 天) dihydrochloride 在 NCI-H1650 NSCLC 异种移植模型中未显示效果,但与 Erlotinib (MS-W28270) 联用时,可达到 98% 的 TGI,且 100% 的受试小鼠出现持续性完全缓解。
Navitoclax (2-6 mg/kg;口服;每日;第 1-6 天 (2 mg/kg),第 7-12 天 (6 mg/kg)) dihydrochloride 可在 Beagle 犬中诱导可逆性血小板减少症,表现为血小板计数初始降低,持续高剂量处理后该降低情况趋于稳定,且无骨髓毒性。

Animal Model: Immunocompromised mice (8-10 mice per group; SKOV3 human ovarian cancer cells flank xenograft model)
Dosage: 100 mg/kg (monotherapy; combination with docetaxel 10 mg/kg; combination with docetaxel 30 mg/kg)
Administration: p.o.; once daily; 2 days, 14 days, 21 days, days 2-3, days 2-15
Result: Showed no antitumor efficacy as monotherapy, with negative or minimal TGI values (-44%, -5%, -4% for 21-day, 14-day, and 2-day daily dosing, respectively) and no ORR.
Increased ORR from 30% to 100%, increased TGI from 82% to 92%, and increased TGD from 114% to >175%, with 33% complete regression when combined with docetaxel (10 mg/kg i.v. once every 7 days for 3 cycles) via concurrent 21-day daily dosing.
Increased ORR from 0% to 89%, increased TGI from 48% to 95%, and increased TGD from 12% to 135%, with 56% complete regression when combined with docetaxel (30 mg/kg i.v. once on day 1) via concurrent 14-day daily dosing.
Increased TGI from 48% to 86% and increased TGD from 12% to 54%, with 11% complete regression and 22% ORR when combined with docetaxel (30 mg/kg i.v. once on day 1) via concurrent 2-day daily dosing.
Increased TGI from 48% to 85% and increased TGD from 12% to 38%, with 11% complete regression and 22% ORR when combined with docetaxel (30 mg/kg i.v. once on day 1) via sequential 14-day daily dosing starting on day 2.
Increased TGI from 48% to 63% and increased TGD from 12% to 38%, with no complete regression or ORR when combined with docetaxel (30 mg/kg i.v. once on day 1) via sequential 2-day daily dosing starting on day 2.
Animal Model: Immunocompromised mice (6 mice per group; NCI-H1650 human NSCLC cells flank xenograft model)
Dosage: 100 mg/kg (monotherapy; combination with erlotinib 50 mg/kg)
Administration: p.o.; once daily; 21 days
Result: Showed no significant antitumor activity as monotherapy.
Increased TGI from 52% to 98%, induced durable complete tumor regressions in 100% of treated mice, and sustained regressions for 25 days after treatment cessation when combined with erlotinib; the combination was well tolerated, with less than 5% body weight loss.

化学信息

分子量 1047.53
分子式 C47H57Cl3F3N5O6S3
CAS No. 1093851-28-5
别名 ABT-263 dihydrochloride

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础